J
Jochen Hess
Researcher at German Cancer Research Center
Publications - 125
Citations - 6990
Jochen Hess is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cancer. The author has an hindex of 39, co-authored 110 publications receiving 6071 citations. Previous affiliations of Jochen Hess include University of Würzburg & Heidelberg University.
Papers
More filters
Journal ArticleDOI
AP-1 subunits: quarrel and harmony among siblings
TL;DR: AP-1-mediated regulation of processes such as proliferation, differentiation, apoptosis and transformation should be considered within the context of a complex dynamic network of signalling pathways and other nuclear factors that respond simultaneously.
Journal ArticleDOI
S100A8 and S100A9 in inflammation and cancer.
TL;DR: Calprotectin expression and potential cytokine-like function in inflammation and in cancer suggests that S100A8/A9 may play a key role in inflammation-associated cancer.
Journal ArticleDOI
RAGE signaling sustains inflammation and promotes tumor development
Christoffer Gebhardt,Astrid Riehl,Moritz Durchdewald,Julia Németh,Gerhard Fürstenberger,Karin Müller-Decker,Alexander Enk,Bernd Arnold,Angelika Bierhaus,Peter P. Nawroth,Jochen Hess,Peter Angel +11 more
TL;DR: It is shown that mice deficient for the receptor for advanced glycation end-products (RAGE) are resistant to DMBA/TPA-induced skin carcinogenesis and exhibit a severe defect in sustaining inflammation during the promotion phase, and direct genetic evidence for a novel role for RAGE in linking chronic inflammation and cancer is provided.
Journal ArticleDOI
Calcium-Binding Proteins S100A8 and S100A9 as Novel Diagnostic Markers in Human Prostate Cancer
Alexander Hermani,Jochen Hess,Barbara De Servi,Senad Medunjanin,Rainer Grobholz,Lutz Trojan,Peter Angel,Doris Mayer +7 more
TL;DR: The data suggest that enhanced expression of S100A8,S100A9, and RAGE is an early event in prostate tumorigenesis and may contribute to development and progression or extension of prostate carcinomas, and S 100A9 in serum may serve as useful marker to discriminate between prostate cancer and BPH.
Journal ArticleDOI
The receptor RAGE: Bridging inflammation and cancer
TL;DR: Molecular mechanisms through which RAGE signalling contributes to the establishment of a pro-tumourigenic microenvironment are summarized and recent findings that provide genetic evidence for an important role of RAGE in bridging inflammation and cancer are reviewed.